Journals / Retina-Vitreus / 2013 / Cilt: 21 - Sayı: 3

Is pharmacotherapy effective for the treatment of proliferative vitreoretinopathy?

Proliferatif vitreoretinopati tedavisinde farmakoterapi etkili mi?

Pages
166–177
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Because the pathogenesis of PVR is complicated, combined therapies which are effective for its every stage are expected to be more successful for the effective pharmacotherapy of PVR

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Proliferative vitreoretinopathy (PVR) is a wound healing process, which is characterized by membrane formation on both surfaces of the retina and in the vitreus as a result of migration and proliferation of cells in these areas.
📊
Key Findings & Data:It is demonstrated that postoperative inflammation is decreased with the use of antiinflammatory agents.
💡
Conclusion & Impact:Because the pathogenesis of PVR is complicated, combined therapies which are effective for its every stage are expected to be more successful for the effective pharmacotherapy of PVR
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Proliferative vitreoretinopathy (PVR) is a wound healing process, which is characterized by membrane formation on both surfaces of the retina and in the vitreus as a result of migration and proliferation of cells in these areas. Contraction of formed membranes causes traction retinal detachment (RD) in the first stage, which in time may result in reopening of preexisting breaks; or new breaks form and rhegmatogenous RD component may be added to the scene. PVR is the most frequent cause of failure after RD sur- gery. Stages in the pathogenesis of PVR in order are, inflammation with activation and proliferation of cells, extracellular matrix formation and remodeling, and contraction. Each stage is a complicated process, in which various molecules and cells play roles. Although, the primary treatment of PVR is a well-performed surgery; multiple phamacological agents can be use to prevent PVR formation or prevent its recurrence as adjuvants to surgery. Antiinflammatory, antiproliferative drugs, and agents that inhibit formation and contraction of extracellular matrix are some of them. As the importance of molecules that play roles in every step of PVR ptahogenesis and genetic predispositions get clear, and as the drugs can be given more efficiently and for longer time, the efficiency of pharmacotherapy of PVR will be more effective. Investigative studies to develop effective drugs for the prophylaxis and treatment PVR without side effects, that will be easily used for long times are currently ongoing. Especially, the prophylaxis of PVR seems to be possible with the current pharmacotherapy options available. It is demonstrated that postoperative inflammation is decreased with the use of antiinflammatory agents. Intraoperative infusion of low molecular weight heparin and 5-fluorouracil is clinically found effective in the prevention of PVR in eyes with high risk for PVR development. The studies that will show the efficacy of isotretinoin in the prophylaxis and treatment of PVR will be announced in the near future, which seem to be hopeful. Because the pathogenesis of PVR is complicated, combined therapies which are effective for its every stage are expected to be more successful for the effective pharmacotherapy of PVR

Özet

Proliferatif vitreoretinopati (PVR), retina altı boşluğa, retina yüzeyine ve vitreus içine hücre göçü ve proliferasyonu sonucu meyda- na gelen, retinanın her iki yüzünde ve vitre içinde membran oluşumu ile karakterize bir yara iyileşmesi sürecidir. Oluşan memb- ranların kontraksiyonu ilk evrede traksiyonel retina dekolmanına (RD) yol açarken, zamanla eski yırtıklar traksiyonla açılabilir veya yeni yırtık oluşumu ile regmatojen RD bileşeni de tabloya eklenir. PVR, RD cerrahisi sonrası başarısızlığın en sık sebebidir. PVR patogenezinde evreler sırasıyla, enflamasyon ile hücrelerin aktivasyonu ve proliferasyonu; ekstraselüler matriks yapımı ve yeniden şekillenmesi; kontraksiyondur. Her evre, çeşitli moleküllerin ve hücrelerin rol oynadığı komplike bir süreçtir. PVR’nin asıl tedavisi iyi bir cerrahi olmakla birlikte, birtakım farmakolojik ilaçlar PVR’nin önlenmesinde veya tekrarının engellenmesinde cerrahiye yardımcı, ek olarak kullanılabilir. Antienflamatuvar, antiproliferatif ilaçlar ile ekstraselüler matriks yapım ve kontrak- siyonunu inhibe edici ajanlar bunlardan bazılarıdır. PVR patogenezinin her aşamasında rol oynayan moleküllerin ve olası genetik predispozisyonların önemi netleştikçe, ilaçların etkin ve uzun süreli verilebilmesi kolaylaştıkça, PVR’nin farmakoterapisi de daha etkin olacaktır. PVR profilaksisi ve tedavisi için hem etkili, hem yan etkileri olmayan, hem de kolay ve uzun süreli uygulanabilen tedavi seçenekleri için deneysel araştırılmalar devam etmektedir. Günümüzdeki farmakoterapi seçenekleriyle PVR’nin özellikle profilaksisi daha mümkün görünmektedir. Antienflamatuvar ajanların postoperatif enflamasyonu anlamlı şekilde azalttığı gös- terilmiştir. Düşük molekül ağırlıklı heparin ile 5-fluorourasilin intraoperatif infüzyonu ise, PVR açısından yüksek riskli gözlerde PVR’nin önlenmesinde klinik uygulamada etkili bulunmuştur. PVR profilaksi ve tedavisinde isotretinoinin etkinliğini gösterecek çalışma sonuçları yakın gelecekte açıklanacaktır ve umut verici görünmektedir. Patogenezi komplike olan PVR’nin etkin farmako- terapisi için, her evresine etkili kombine tedaviler daha başarılı olacak gibi görünmektedir

🔖

Cite This Article

ACAR, N. (2013). Is pharmacotherapy effective for the treatment of proliferative vitreoretinopathy?. Retina-Vitreus, Cilt: 21 - Sayı: 3, 166–177. https://ajindex.com/articles/305050

References (13)

  1. Scott IU, Flynn HW Jr, Murray TG, et al. Perfluoron study group. Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: a multicenter study. Am J Ophthalmol 2003;136:454-63
  2. Silicone Study Report 2. Vitrectomy with silicone oil or per- fluoropropane gas in eyes with severe proliferative vitreoreti- nopathy: results of a randomized clinical trial. Arch Ophthal- mol 1992;110:780-92
  3. Asaria RH, Kon CH, Bunce C, et al. How to predict prolifera- tive vitreoretinopathy: a prospective study. Ophthalmology 2001;108:1184-6
  4. McCuen BW 2nd, Azen SP, Stern W, et al. Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe pro- liferative vitreoretinopathy. Silicone Study Report 3. Retina 1993;13:279-84
  5. Abrams GW, Azen SP, McCuen BW 2nd, et al. Vitrectomy with silicone oil or long-acting gas in eyes with severe pro- liferative vitreoretinopathy: results of additional and long- term follow-up. Silicone Study report 11. Arch Ophthalmol 1997;115:335-44
  6. Campochiaro PA. The pathogenesis of proliferative vitreo- retinopathy. In: Ryan SJ: Retina, Mosby, Elsevier USA 2006;2235-6
  7. Pastor JC, de la Rúa ER, Martín F. Proliferative vitreoreti- nopathy: risk factors and pathobiology. Prog Retin Eye Res 2002;21:127-44. 8
  8. Rojas J, Fernandez I, Pastor JC, et al. A strong genetic as- sociation between the tumor necrosis factor locus and prolif- erative vitreoretinopathy: the retina 4 project. Ophthalmology 2010;117:2417-23. Vidaurri-Leal J, Hohman R, Glaser BM. Effect of vitreous on morphologic characteristics of retinal pigment epithelial cells. A new approach to the study of proliferative vitreoretinopa- thy. Arch Ophthalmol1984;102:1220-3
  9. Campochiaro PA, Glaser BM. Mechanisms involved in reti- nal pigment epithelial cell chemotaxis. Arch Ophthalmol 1986;104:277-80
  10. Lei H, Velez G, Hovland P, et al. Growth factors outside the PDGF family drive experimental PVR. Invest Ophthalmol Vis Sci 2009;50:3394-403
  11. Rasier R, Gormus U, Artunay O, et al. Vitreous levels of VEGF, IL-8, and TNF-alpha in retinal detachment. Curr Eye Res 2010;35:505-9
  12. Campochiaro PA, Bryan JA 3rd, Conway BP, et al. In- travitreal chemotactic and mitogenic activity. Implica- tion of blood-retinal barrier breakdown. Arch Ophthalmol 1986;104:1685-7
  13. Glaser BM, Cardin A, Biscoe B. Proliferative vitreoretinopa- thy. The mechanism of development of vitreoretinal traction. Ophthalmology 1987;94:327-